The first combination booster vaccine against pertussis, tetanus, and
diphtheria for adolescents has been approved by the Food and Drug Administration.
It will be marketed as Boostrix by GlaxoSmithKline Inc (Brentford, Middlesex,
England) and indicated for use as a single booster dose to adolescents aged
10 to 18 years.
Although combination booster vaccines exist against tetanus and diphtheria,
this is the first to include pertussis, a highly communicable disease that
can be particularly serious for infants. The disease is usually less severe
in adolescents, but they may transmit it to susceptible infants and other
family members. In the last 20 years, rates of pertussis infection have been
Hampton T. New Combination Vaccine. JAMA. 2005;293(24):2992. doi:10.1001/jama.293.24.2992-a